Strata Critical Medical (NASDAQ: SRTA) reported second-quarter fiscal year 2026 revenue of $72.5 million, marking a 60.7% increase from the prior-year period. The growth was driven by strong performance in the clinical segment and contributions from recent acquisitions.

The company raised its full-year 2026 revenue guidance to $285–$295 million and adjusted EBITDA guidance to $33–$35 million, reflecting accelerated clinical growth and acquisition synergies. Clinical revenue rose 22.6% sequentially to $24.3 million, while logistics revenue grew 1% sequentially.

Segment Performance

The clinical business emerged as the primary growth driver, with organic clinical revenue (excluding Q2 acquisitions) rising 15.1% sequentially. Transplant clinical revenue specifically surged 23.8%. Gross margins in the clinical segment improved to 26.1% in Q2FY26, up from 25% in Q1FY26.

In contrast, the logistics segment faced headwinds. Revenue increased 6.9% year-over-year but saw only marginal sequential growth. Logistics gross margin declined to 18.4% from 19.3% in the previous quarter, impacted by higher fuel surcharges and unfavorable customer mix shifts toward shorter trips.

Strategic Acquisitions and Guidance

Strata Critical Medical completed three strategic acquisitions in Q2FY26, including Louisville Perfusion Services, Ohio Valley Perfusion Associates, and Heart and Lung Transplant National Recovery Program. These deals are projected to add $6.3 million to annualized adjusted EBITDA. The company also signed an agreement to transition Statline’s transplant center organ placement customers, potentially adding up to eight new clients over the next 12 months.

Management expects clinical revenue to grow approximately 20% sequentially in Q3FY26. However, logistics revenue is projected to decrease by high single digits sequentially due to a 3% revenue headwind from one non-exclusive customer reducing flight volumes. This impact is expected to be mitigated by new customer wins in Q4FY26.

What the Numbers Show

A divergence exists between top-line growth and margin stability. While total revenue expanded significantly due to acquisitions and clinical demand, logistics gross margins contracted to 18.4%, below the company’s 20% target. The exclusion of fuel surcharge revenue reveals a logistics gross margin of 19%, indicating that structural cost pressures and mix shifts are more persistent than temporary fuel adjustments. Furthermore, free cash flow of $2.9 million trails adjusted EBITDA of $7.9 million by $5 million, primarily driven by a $1.7 million working capital build associated with rapid clinical expansion.

Strata Critical Medical (NASDAQ: SRTA) reported second-quarter 2026 revenue of $72.5 million, a 60.7% increase from $45.1 million in the same period last year, driven by robust growth in its clinical services segment and the integration of recent acquisitions. The company generated $7.9 million in adjusted EBITDA, up from $6.4 million in Q1 2026, as it executed three strategic bolt-on acquisitions that added over $20 million in annualized revenue. Co-CEOs Melissa Tomkiel and Will Heyburn highlighted that the business mix is shifting toward higher-margin clinical services, which now represent approximately 40% of revenue compared to 30% in Q1 2026.

The earnings call, hosted on Tuesday, featured discussions on the company’s capital deployment plan and operational updates. Management noted that while logistics revenue faced a 3% headwind due to reduced flying with a non-exclusive customer, the long-term outlook remains positive. The company also disclosed that it expects to receive a $17.5 million performance earnout from Joby Aviation by year-end. Forward-looking statements were made in accordance with the Private Securities Litigation Reform Act of 1995, with risks detailed in SEC filings Form 10-K and Form 10-Q.

Financial Performance

Total revenue surged to $72.5 million in Q2 2026, reflecting both organic strength and acquisition impacts. Clinical revenue rose 22.6% sequentially to $24.3 million, with organic growth excluding acquisitions reaching 15.1%. Gross profit increased 68.9% to $15.2 million, lifting the overall gross margin to 21% from 20% in the prior-year period. Adjusted SG&A remained stable at $9.1 million, down slightly from $9.2 million in Q1 2026.

Logistics revenue grew 6.9% year-over-year but faced margin pressure, falling to 18.4% from 19.3% in Q1 2026. This decline was attributed to higher fuel surcharges, which pass through costs without impacting gross profit dollars, and an unfavorable shift toward shorter, lower-margin trips. However, gross margin excluding fuel surcharge was 19%, indicating underlying stability. Management expects logistics margins to recover to the 18.5%-20% range in the second half of 2026 and reach the 20% target by 2027.

Strategic Acquisitions and Clinical Growth

Strata Critical Medical completed three acquisitions in Q2 2026 at mid-single-digit multiples, enhancing its national footprint and operational efficiency. These included Louisville Perfusion Services, Ohio Valley Perfusion Associates, and the Heart and Lung Transplant National Recovery Program. Collectively, these deals contribute over $20 million in revenue and $6.3 million in projected annualized adjusted EBITDA. Additionally, the company signed an agreement to transition Statline’s transplant center organ placement relationships over the next 12 months, creating attachment points for up to eight new customers.

The clinical segment’s gross margin improved to 26.1% in Q2 2026, up from 25% in Q1 2026, driven by the higher-margin transplant clinical business. Will Heyburn noted that the strategic shift toward clinical services, which are less capital-intensive than logistics, positions the company for stronger cash generation. The company generated $5.7 million in operating cash flow and $2.9 million in free cash flow, marking the second consecutive quarter of positive free cash flow.

What the Numbers Show

The divergence between revenue growth and logistics margin performance highlights the transitional nature of Strata Critical Medical’s business model. While total revenue jumped 60.7% year-over-year, this was largely fueled by the addition of clinical businesses acquired in late 2025 and during Q2 2026, rather than pure organic volume growth in the legacy logistics segment. The fact that adjusted EBITDA margin expanded to 10.9% from 9.5% sequentially, despite logistics margin compression, underscores the accretive nature of the clinical acquisitions. Investors should note that the $17.5 million Joby earnout, expected by year-end, will provide a significant one-time cash boost, though it does not reflect recurring operational profitability. The company’s ability to restore logistics margins to 20% by 2027 remains critical to sustaining long-term earnings power without relying solely on M&A.